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Summary
Background.— Limited French data are available for the different clinical types (paroxysmal,
persistent and permanent) of atrial ﬁbrillation and their comorbidities (AF).
Aims.— To provide contemporary insights into the characteristics and management of outpa-
tients with a history of or current AF in France.Healthcare resource;
Therapeutic strategy
Methods.— EPHA is a national, observational, cross-sectional, multicentre descriptive study
with retrospective data collection relating to the management, treatment and hospitalization
of patients with AF.
Results.— One thousand three hundred and thirty-one patients (mean age: 74± 11 years
[55.7%≥ 75 years]; 58.8% men) were included into the study between February 2009 and May
2009; their data were collected during the past 12 months. Of these, 38.2% had paroxysmal AF,
 This paper has been edited by Yves Juillière MD, PhD, Deputy Editor.
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1 A complete list of EPHA Investigators is detailed in the Appendix.
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10.0% persistent AF and 51.8% permanent AF. Most patients had at least one cardiovascular
risk factor (80.8%). Almost all patients (96.6%) had received an antiarrhythmic drug in the
previous year, of which 59.6% received a rhythm control strategy (class I, class III) with or
without rate control strategy (class II, class IV, digitalis) and 40.6% received a rate control
strategy exclusively. Almost all (94.4%) patients were treated with an antithrombotic: 83.4%
with a vitamin K antagonist and 21.9% with antiplatelet therapy. Almost one-ﬁfth (18.4%) of
patients had been hospitalized related to AF at least once in the previous year. Patients with
paroxysmal and persistent AF were hospitalized more frequently (20.0% and 31.1%, respectively)
than patients with permanent AF (14.8%).
Conclusions.— About half of the patients had paroxysmal or persistent AF. Four-ﬁfths of AF
patients had at least one cardiovascular risk factor. The use of antiarrhythmic and antithrom-
botic treatments was very high. The rhythm control strategy was preferred in patients with
paroxysmal or persistent AF.
© 2010 Published by Elsevier Masson SAS.
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Résumé
Introduction.— Il existe peu de données franc¸aises sur les différents types cliniques de ﬁbril-
lation auriculaire (FA) (paroxystique, persistante ou permanente) et leurs comorbidités.
Objectif.— Décrire les caractéristiques et la prise en charge des patients ambulatoires présen-
tant un antécédent de FA ou actuellement en FA, en France.
Méthodes.— L’étude EPHA est une étude franc¸aise, observationnelle, transversale, multicen-
trique descriptive avec recueil rétrospectif des données de prise en charge, de traitement et
d’hospitalisation des patients atteints de FA.
Résultats.— Mille trois cent trente-et-un patients (âge moyen : 74± 11 ans [55,7 %≥ 75 ans] ;
58,8 % de sexe masculin) ont été inclus dans l’étude entre février 2009 et mai 2009, les données
ont été recueillies sur les 12 derniers mois. Parmi ces patients, 38,2 % avaient une FA paroxys-
tique, 10 % une FA persistante et 51,8 % une FA permanente. La majorité de ces patients avait
au moins un facteur de risque cardiovasculaire (80,8 %). La quasi-totalité des patients (96,6 %)
étaient sous traitement antiarythmique dans l’année précédant l’inclusion. Parmi les patients
traités, 59,6 % recevaient un traitement de contrôle du rythme (antiarythmiques de classe I ou
III) avec ou sans traitement de contrôle de la fréquence cardiaque (antiarythmiques de classe II,
de classe IV ou digitaliques) et 40,6 % recevaient exclusivement un traitement de contrôle de la
fréquence cardiaque. La majorité des patients (94,4 %) recevaient un antithrombotique : 83,4 %
un antivitamine K et 21,9 % un antiplaquettaire. Près d’un cinquième des patients (18,4 %) ont
été hospitalisés au moins une fois pour raison cardiovasculaire liée à la FA dans l’année précé-
dente. Les patients en FA paroxystique ou persistante ont plus souvent été hospitalisés (20,0 %
et 31,1 %, respectivement) que les patients en FA permanente (14,8 %).
Conclusion.— Environ la moitié des patients avaient une FA paroxystique ou persistante. Quatre
patients sur cinq en FA avaient au moins un facteur de risque cardiovasculaire. L’utilisation de
traitements antiarythmiques et antithrombotiques était très élevée. Une stratégie de contrôle
du rythme était plus fréquent chez les patients en FA paroxystique ou persistante que chez les
patients en FA permanente. Ces résultats soulignent la nécessité de traitements ou techniques
avec un meilleur rapport bénéﬁce—risque aﬁn d’optimiser la prise en charge de cette pathologie
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Introduction
Atrial ﬁbrillation (AF) is the most frequently observed car-
diac arrhythmia in clinical practice. It is a major cause
of long-term morbidity and mortality including major car-
diovascular events as ischaemic stroke, heart failure and
all-cause death [1—3]. One in six strokes occurs in patients
with AF [4], and mortality in these patients is about double
that of subjects in sinus rhythm and is related directly to
the severity of underlying heart disease [4].
The estimated prevalence of AF ranges from 0.4—1% in
the general population, rising to 8% in patients older than
t
d
o
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n SAS.
0 years [4,5]. AF affects around 2.2 million people in the
nited States and 4.5 million in Europe [6]; between 600,000
nd one million patients in France are estimated to have AF
6—8]. These ﬁgures will escalate with the ageing of the
opulation, leading to increasing healthcare expenses of AF
anagement.
AF can be deﬁned as paroxysmal (AF that terminates
pontaneously and generally lasts≤ 7 days), persistent (AF
hat does not terminate spontaneously and usually lasts > 7
ays), and permanent (AF in which cardioversion has failed
r has not been attempted). When a patient has had two
r more episodes, AF is considered recurrent. The distribu-
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ion of clinical AF types varies in France [9,10]. Permanent
F is diagnosed in 30—50% of AF cases, with paroxysmal
r persistent AF accounting for the remaining 50—70%. To
he best of our knowledge, there is no recent French epi-
emiological study describing the different types of AF and
ge, comorbidities and treatment. The Euro Heart Survey
ecently described treatment and prognosis up to 1 year,
ccording to type of AF, in subjects in 35 European countries,
ut included only 51 patients from France [11,12].
The primary objective of the present study is to describe
he distribution of clinical AF types in patients with a
istory of or current AF who were being followed-up by
ardiologists in France. The secondary objectives are: to
etermine the patients’ characteristics, cardiovascular risk
actors, and comorbidities for each type of AF; to describe
reatment strategies during the past year; to describe the
ardiovascular hospitalizations related to AF and to its
omplications; and to estimate the healthcare resources
onsumed.
ethods
PHA is a national, observational, cross-sectional, multi-
entre descriptive study with retrospective data collection
elating to the management, treatment and hospitalization
f patients with AF.
hysician selection
hree thousand cardiologists were identiﬁed at random from
comprehensive national database (TVF physician identiﬁ-
ation database) of all cardiologists in France. The aim was
o enrol 300 physicians, 100 from hospital-based practices
nd 200 from ofﬁce-based or both hospital- and ofﬁce-based
ractices willing to participate in the study. Each cardi-
logist completed a standardized case report form that
ollected information about their age, sex, year of grad-
ation, department of practice, type of practice (ofﬁce-
r hospital-based practice), mean number of patients seen
ach month, and mean number of patients seen each month
ith a history of or current documented AF.
The representativeness of the physician sample was
hecked by comparing the distribution of participating car-
iologists with national statistics published by the Direction
e la recherche, des études, de l’évaluation et des statis-
iques (DREES) [13], in order to verify the lack of selection
iases. The physicians enrolled patients seen during the
ourse of normal clinical practice and no changes were
mposed by the study in the diagnosis and treatment of these
ndividuals.
atient selection
nvestigating physicians undertook to include the ﬁrst eight
onsecutive patients who fulﬁlled the inclusion criteria,
ntil 1300 patients had been enrolled.Men and women aged≥ 18 years were eligible for inclu-
ion if they had been seen in consultation, and monitored, by
cardiologist for at least 1 year; had a history of or current
ocumented AF (on an electrocardiogram [ECG] or Holter
CG) for at least 1 year, irrespective of the rhythm on the day
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f inclusion; and provided written informed consent before
articipating in the study.
Patients were excluded from this study if they pre-
ented with AF due to a transient cause (e.g., thyrotoxicosis,
xcessive alcohol intake, myocarditis, pericarditis, acute
yocardial infarction, pulmonary embolism, metabolic dis-
urbances or electrocution), with AF following cardiac
urgery within the past 3 months or had not been monitored
egularly by the investigator (last visit > 12 months before
nclusion).
Cardiologists completed case report forms that collected
ata on the patient’s demographics, cardiovascular risk fac-
ors, medical history, clinical examination, characteristics
f AF, electrocardiographic and echocardiographic data,
iological data, management of AF during the past 12
onths, and healthcare resources related to AF manage-
ent (including number of hospitalizations related to AF).
irect healthcare resources only were considered.
tatistical methods
he sample size was determined in order to have a degree
f precision≥ 2.5% to describe the different types of AF,
300 patients needed to be enrolled. For the statistical
nalysis, prespeciﬁed descriptive analyses were performed.
hese analyses (percentages and means) are based on the
umber of non-missing values for each variable. All cate-
orical variables were tested between the three types of AF
sing chi-square, and continuous variables using analysis of
ariance.
The study protocol was submitted to two national author-
ties, Comité consultatif sur le traitement de l’information
n matière de recherche dans le domaine de la santé
CCTIRS) and Commission nationale de l’informatique et
es libertés (CNIL), and was conducted in accordance with
rench law and the declaration of Helsinki.
esults
tudy population
f 416 cardiologists who agreed to participate, 234 enrolled
t least one patient into the study. A total of 1470 patients
ere enrolled between 25 February and 6 May 2009. Of
hese, 41 did not provide written informed consent and were
xcluded from the study. A further 98 did not fulﬁl the inclu-
ion criteria. The analysis is therefore based on data from
331 patients.
atient characteristics at consultation
he characteristics of the 1331 patients included in the
tudy are shown in Table 1. The mean age was 74± 11 years
55.7% were≥ 75 years) and 58.8% were men. Over half of
he 1331 patients enrolled had permanent AF (51.8%, 95%
I 49.2—54.5), 38.2% (95% CI 35.6—40.8) had paroxysmal
F and 10.0% (95% CI 8.4—11.6) had persistent AF. Younger
atients were more likely to present paroxysmal or per-
istent AF, whereas older patients (≥ 75 years) more often
resented permanent AF (Fig. 1).
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Table 1 Patient demographics and characteristics overall and according to type of atrial ﬁbrillation.
Paroxysmal AF
(n = 508)
Persistent AF
(n = 133)
Permanent AF
(n = 690)
p valuea Total
(n = 1331)
Demographics
Men 292 (57.5) 80 (60.2) 411 (59.6) 0.73 783 (58.8)
Age, years 71± 11 72± 11 76± 9 < 0.001 74± 11
≥ 75 years 221 (43.5) 64 (48.1) 457 (66.2) < 0.001 742 (55.7)
Cardiovascular risk factors
≥ 1 risk factor 406 (80.1) 108 (81.2) 560 (81.3) 0.87 1074 (80.8)
Hypertension 318 (78.3) 93 (86.1) 450 (80.4) 0.19 861 (80.2)
Diabetes mellitus 71 (17.5) 23 (21.3) 121 (21.6) 0.27 215 (20.0)
Dyslipidaemia 244 (60.1) 61 (56.5) 320 (57.3) 0.64 625 (58.3)
Smoking history
Current 29 (7.1) 6 (5.6) 26 (4.7) 0.30 61 (5.7)
Stopped < 3 years 15 (3.7) 3 (2.8) 13 (2.3) 31 (2.9)
Stopped≥ 3 years 107 (26.4) 38 (35.2) 163 (29.2) 308 (28.7)
Family history of premature
CVD
Paternalb 25 (7.4) 9 (11.3) 28 (6.6) 0.35 62 (7.4)
Maternalc 14 (4.1) 4 (5.0) 10 (2.4) 0.28 28 (3.3)
Early stroke (< 45 years) 4 (1.2) 4 (5.0) 1 (0.2) 0.003 9 (1.1)
No family history of premature CVD 301 (88.5) 66 (82.5) 386 (91.5) 0.0448 753 (89.4)
Medical history and comorbidities
≥ 1 medical history/comorbidity 365 (72.0) 103 (77.4) 598 (87.0) < 0.001 1066 (80.3)
Heart failure 65 (17.8) 29 (28.2) 250 (41.8) < 0.001 344 (32.3)
NYHA class I 15 (23.1) 7 (24.1) 31 (12.5) 0.13 53 (15.5)
NYHA class II 39 (60.0) 15 (51.7) 170 (68.5) 224 (65.5)
NYHA class III 11 (16.9) 6 (20.7) 44 (17.7) 61 (17.8)
NYHA class IV 0 1 (3.4) 3 (1.2) 4 (1.2)
Ischaemic stroke 29 (7.9) 9 (8.7) 45 (7.5) 0.91 83 (7.8)
Transient ischaemic attack 31 (8.5) 5 (4.9) 40 (6.7) 0.37 76 (7.1)
Ischaemic heart disease 82 (22.5) 29 (28.2) 165 (27.6) 0.18 276 (25.9)
Non-ischaemic heart disease 101 (27.7) 25 (24.3) 200 (33.4) 0.058 326 (30.6)
Valvular disease 108 (29.6) 32 (31.1) 258 (43.1) < 0.001 398 (37.3)
Rheumatic 18 (16.7) 6 (18.8) 71 (27.6) 0.063 95 (23.9)
Pulmonary disease 51 (14) 20 (19.4) 80 (13.4) 0.26 151 (14.2)
Thyroid disease 62 (17.0) 14 (13.6) 86 (14.4) 0.49 162 (15.2)
Hypothyroidism 51 (82.3) 9 (69.2) 60 (73.2) 0.36 120 (76.4)
Hyperthyroidism 11 (17.7) 4 (30.8) 22 (26.8) 37 (23.6)
Chronic renal insufﬁciency 30 (8.2) 7 (6.8) 54 (9.0) 0.73 91 (8.5)
Sleep apnea syndrome 27 (7.4) 10 (9.7) 40 (6.7) 0.54 77 (7.2)
Pacemaker 65 (17.8) 10 (9.7) 138 (23.1) 0.0032 213 (20.0)
Data given as n (%) or mean± standard deviation.
CVD: cardiovascular disease; NYHA: New York Heart Association.
a Analysis of variance or chi-square.
b MI or sudden death before age 55 in father or parent of ﬁrst-degree male relative.
greec MI or sudden death before age 65 in mother or parent of ﬁrst-deCardiovascular risk factors, medical history and
comorbidities
Most patients (80.8%) had at least one cardiovascular
risk factor, including hypertension (80.2%), dyslipidaemia
(
(
p
ofemale relative.58.3%), a history of or current tobacco consumption
37.3%), diabetes mellitus (20.0%) and a family history of
remature cardiovascular disease (10.6%). The proportion
f patients with at least one cardiovascular risk factor was
380 A. Cohen et al.
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tigure 1. Age distribution for men and women enrolled in the EP
imilar irrespective of the type of AF (80.1% for paroxysmal,
1.2% for persistent, 81.3% for permanent) (Table 1).
Almost one-third of patients with AF had a history of
eart failure, which was most frequent among the group
ith permanent AF (41.8% vs. 28.2% for persistent AF and
7.8% for paroxysmal AF, p < 0.001). Patients with perma-
ent AF more often had New York Heart Association class
II—IV heart failure (6.8%) compared to patients with parox-
smal or persistent AF (2.8%). Eight per cent had a history
f ischaemic stroke; 25.9% had ischaemic heart disease;
0.6% had non-ischaemic heart disease; and 37.3% had valvu-
ar disease. Patients with permanent AF more often had
alvulopathy (43.1%) compared to patients with persistent
31.1%) or paroxysmal (29.6%) AF; one-ﬁfth of patients had
pacemaker.
Overall, 15.2% had thyroid disease, most commonly
ypothyroidism (76.4%), and 8.5% had chronic renal insuf-
ciency, but there was no signiﬁcant difference in the
revalences across AF types.
HADS2 score at study entry
he mean CHADS2 [14] (heart failure, hypertension, age≥ 75
ears, diabetes, stroke or transient ischaemic attack [TIA])
core was highest in patients with permanent AF, intermedi-
te in those with persistent AF and lowest in patients with
aroxysmal AF (p < 0.001) (Table 2). One-third of patients
ith permanent AF were at high risk of a stroke (CHADS2
core > 2) vs. 27.8% of those with persistent AF and 17.1%
ith paroxysmal AF.
Overall, 71.6% of outpatients with AF were being man-
ged for a long-term illness (i.e., France-speciﬁc, fully
eimbursed condition or affection de longue durée [ALD]),
1.4% with paroxysmal AF, 60.9% with persistent AF, and
1.2% with permanent AF. The most frequent long-term ill-
ess was linked to a cardiovascular disease (89.1%).
haracteristics of the AFhe mean time since diagnosis of AF was 6.1± 5.3 years and
iffered signiﬁcantly depending on AF type: 7.0± 5.5 years
or permanent AF, 5.3± 5.0 years for paroxysmal AF and
.9± 5.0 years for persistent AF (p < 0.001). The majority
f patients had symptomatic AF (59.1%), with no differ-
w
m
(
tudy (p < 0.001 for trend).
nces by clinical type, whereas symptoms varied according
o AF type: palpitations were most frequent in patients with
aroxysmal or persistent AF; dyspnoea was more common in
atients with permanent or persistent AF (Table 3).
anagement in previous 12 months
ardioversion
uring the year before enrolment into the study, 12.1%
f patients had undergone a cardioversion (pharmacologi-
al in 48.4%, electrical in 25.8%, both in 30.3%). The last
ttempted cardioversion had been successful in 74.1% of the
atients and was least successful in patients with permanent
F (Table 4).
harmacological treatment
lmost all (96.6%) patients had received an antiarrhyth-
ic drug in the previous year and 3.4% were not treated
Table 4). Among these treated patients, 40.6% of patients
eceived a rate control strategy (class II, class IV, digitalis)
xclusively; the remaining patients received either a rhythm
ontrol strategy (class I, class III) or both rhythm and rate
ontrol strategies. A rhythm control strategy (exclusively or
ith rate control strategy) was preferred in patients with
aroxysmal AF (58% exclusively; 89,6% both) and in patients
ith persistent AF (44% exclusively; 75,4% both). A rate con-
rol strategy alone was preferred in patients with permanent
F (69.3% vs. 24.6% in persistent AF and 10.4% in paroxys-
al AF; p < 0.001). The most frequently used antiarrhythmic
rugs in the overall population were class II (41.2%), fol-
owed by amiodarone (32.5%) and class Ic sodium channel
lockers (24.1%) (Table 4). Overall, 27.4% of patients had
iscontinued or changed of antiarrhythmic treatment over
he previous 12 months, which was more frequently among
aroxysmal (30%) and persistent (43%) than permanent (22%)
F patients (p < 0.001) (Table 4). The main reasons for
herapy discontinuation were adverse events (40.9%) and
herapeutic escape (40.9%).At enrolment into the study, almost all (94.4%) patients
ere treated with an antithrombotic: 83.4% with a vita-
in K antagonist and 21.9% with antiplatelet therapy
Table 4). Patients with permanent AF were more frequently
reated with an antithrombotic (99.1%) than patients with
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Table 2 Electrocardiogram, electrocardiography characteristics, physical and biological examination, according to type
of atrial ﬁbrillation.
Paroxysmal AF
(n = 508)
Persistent AF
(n = 133)
Permanent AF
(n = 690)
p valuea Total
(n = 1331)
Reason for consultation
AF monitoring 367 (72.7) 104 (78.8) 480 (70.3) 0.12 951 (72.0)
Other reason 122 (24.2) 23 (17.4) 165 (24.2) 310 (23.5)
Both 16 (3.2) 5 (3.8) 38 (5.6) 59 (4.5)
Mean time since diagnosis of
AF (years)
5.3 (5.0) 4.9 (4.9) 7.0 (5.5) < 0.001 6.1 (5.3)
Symptoms
None 216 (43.1) 48 (36.1) 272 (40.1) 0.29 536 (40.9)
Palpitations 186 (37.1) 48 (36.1) 84 (12.4) < 0.001 318 (24.2)
Dyspnoea 143 (28.5) 54 (40.6) 354 (52.2) < 0.001 551 (42.0)
Asthenia 70 (14.0) 35 (26.3) 135 (19.9) 0.0014 240 (18.3)
Chest pain 27 (5.4) 5 (3.8) 20 (2.9) 0.10 52 (4.0)
Lipothymia 34 (6.8) 2 (1.5) 17 (2.5) < 0.001 53 (4.0)
Syncope 4 (0.8) 0 1 (0.1) 0.23 5 (0.4)
Other 11 (2.2) 2 (1.5) 8 (1.2) 0.39 21 (1.6)
Physical examination
BMI (kg/m2) 26.6± 4.6 27.8± 5.7 27.04± 4.8 0.04 27.0± 4.9
< 25 kg/m2 203 (40.0) 38 (28.8) 244 (35.6) 0.10 485 (36.6)
25—30 kg/m2 199 (39.3) 60 (45.5) 270 (39.4) 529 (39.9)
> 30 kg/m2 105 (20.7) 34 (25.8) 172 (25.1) 311 (23.5)
Systolic BP (mmHg) 136.8± 16.3) 138.5± 17.5 134.0± 15.4 0.001 135.5± 16.0
Diastolic BP (mmHg) 77.4± 9.2 79.5± 9.7 77.3± 8.8 0.03 77.6± 9.0
ECG characteristics
Sinus rhythm 423 (85.3) 59 (45.0) 0 482 (37.0)
AF 38 (7.7) 65 (49.6) 637 (94.1) 740 (56.7)
Atrial ﬂutter 5 (1.0) 3 (2.3) 20 (3.0) 28 (2.1)
Heart rate (bpm) 66.4± 14.1 76.8± 20.6 74.5± 13.6 < 0.001 71.6± 15.2
QT (ms) 380.7± 108.1 347.4± 136.1 346.0± 122.1 < 0.001 360.3± 119.4
LVH 52± 10.9 12± 9.4 87± 13.8 0.21 151± 12.2
Sokoloff index 22.7± 8.8 23.1± 9.8 23.6± 9.5 0.32 23.2± 9.3
Negative T wave 94 (19.3) 27 (21.6) 223 (34.5) < 0.001 344 (27.3)
Echocardiography 386 (76.0) 109 (82.0) 519 (75.2) < 0.001 1014 (76.3)
Mean time since
echocardiography, days
99.31± 110.32 93.86± 97.83 89.54± 104.21 0.40 93.71± 105.92
Diameter of left atrium,
mm (mean)
40.99± 7.31 43.19± 7.47 47.81± 8.72 < 0.001 44.72± 8.69
Surface area of left
atrium, cm2 (mean)
23.33± 7.87 25.56± 8.25 30.27± 10.42 < 0.001 27.15± 9.87
LVEF, % (mean) 62.81± 11.08 60.74± 11.50 58.02± 12.45 < 0.001 60.12± 12.05
Shortening fraction, %
(mean)
36.37± 9.06 34.86± 8.14 33.14± 9.37 < 0.001 34.55± 9.24
Biological examination
Creatininaemia (mean),
mol/L
98.38± 38.93 96.15± 31.37 101.25± 43.34 0.40 99.65± 40.64
Kalaemia, meq/L 4.30± 0.40 4.28± 0.48 4.37± 0.44 0.04 4.33± 0.43
INR (mean) 2.33± 0.64 2.51± 0.79 2.53± 0.61 < 0.001 2.47± 0.65
Data given as number (%) or mean± SD unless otherwise stated.
AF: atrial ﬁbrillation; ECG: electrocardiogram; LVEF: left ventricular ejection fraction; INR: international normalized ratio; LVH: left
ventricular hypertrophy; MI: myocardial infarction.
a Chi-square or analysis of variance.
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Table 3 CHADS2 score overall and according to type of atrial ﬁbrillation.
Paroxysmal
AF (n = 508)
Persistent
AF (n = 133)
Permanent
AF (n = 690)
p valuea Total
(n = 1331)
CHADS2 score 1.49± 1.13 1.72± 1.29 2.04± 1.20 < 0.001 1.80± 1.21
0 100 (19.7) 29 (21.8) 64 (9.3) < 0.001 193 (14.5)
1 177 (34.8) 29 (21.8) 170 (24.6) 376 (28.2)
2 144 (28.3) 38 (28.6) 233 (33.8) 415 (31.2)
> 2 87 (17.1) 37 (27.8) 223 (32.3) 347 (26.1)
a Chi-square or analysis of variance.
Table 4 Management of atrial ﬁbrillation overall and according to type of atrial ﬁbrillation.
Paroxysmal
AF (n = 508)
Persistent
AF (n = 133)
Permanent
AF (n = 690)
p valuea Total
(n = 1331)
Cardioversion in the past year 74 (14.6) 40 (30.5) 46 (6.7) < 0.001 160 (12.1)
Number 1.1 (0. 5) 1.2 (0.4) 1.2 (0.5) 0.49 1.2 (0.4)
Type of cardioversion
Electrical 20 (27.0) 10 (26.3) 10 (23.3) 0.90 40 (25.8)
Pharmacological 42 (56.8) 18 (47.4) 15 (34.9) 0.07 75 (48.4)
Pharmacological followed by
electrical
14 (18.9) 12 (31.6) 21 (48.8) 0.003 47 (30.3)
Success of last attempted cardioversion 65 (92.9) 31 (91.2) 13 (30.2) < 0.001 109 (74.1)
Antiarrhythmic treatment 12 months
before enrolment
480 (97.6) 118 (95.2) 573 (96.1) 0.28 1171 (96.6)
Class Ia 10 (2.1) 1 (0.8) 1 (0.2) 0.007 12 (1.0)
Class Ib 1 (0.2) 0 0 0.51 1 (0.1)
Class Ic 211 (44.0) 37 (31.4) 34 (5.9) < 0.001 282 (24.1)
Class II (beta-blocker) 149 (31.0) 46 (39.0) 288 (50.3) < 0.001 483 (41.2)
Class III (potassium channel blocker)
Sotalol 53 (11.0) 6 (5.1) 24 (4.2) < 0.001 83 (7.1)
Amiodarone 199 (41.5) 54 (45.8) 128 (22.3) < 0.001 381 (32.5)
Other 0 0 7 (1.2) 0.031 7 (0.6)
Class IV (calcium channel blocker) 21 (4.4) 9 (7.6) 46 (8.0) 0.049 76 (6.5)
Digitalis (digoxin) 43 (9.0) 20 (16.9) 269 (46.9) < 0.001 332 (28.4)
Types of treatment 12 months before
enrolment
< 0.001
Rate control 50 (10.4) 29 (24.6) 397 (69.3) 476 (40.6)
Rhythm control 278 (57.9) 52 (44.1) 81 (14.1) 411 (35.1)
Both 152 (31.7) 37 (31.4) 95 (16.6) 284 (24.3)
Discontinuation or change of
antiarrhythmic treatment
146 (29.7) 54 (43.5) 128 (22) < 0.001 328 (27.4)
Reason: adverse events 57 (39.0) 18 (33.3) 59 (46.1) 0.23 134 (40.9)
Reason: therapeutic escape 68 (46.6) 28 (51.9) 38 (29.7) 0.004 134 (40.9)
Treatments taken at enrolment
Antithrombotic 450 (88.6) 123 (92.5) 684 (99.1) < 0.001 1257 (94.4)
Vitamin K antagonist 309 (68.7) 103 (84.4) 635 (93.0) < 0.001 1047 (83.4)
Antiplatelet 159 (35.3) 21 (17.2) 95 (13.9) < 0.001 275 (21.9)
Antihypertensive 356 (70.1) 103 (77.4) 538 (78.1) 0.005 997 (75.0)
Hypolipaemic 230 (45.5) 60 (45.1) 327 (47.7) 0.69 617 (46.6)
a Chi-square or analysis of variance.
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paroxysmal (88.6%) or persistent (92.5%) AF (p < 0.001).
Three-quarters of the patients were treated with antihy-
pertensive therapy. The main antihypertensive treatments
were: diuretics (55.3%), angiotensin II receptor antagonist
(40.3%), beta-blockers (38.7%) and ACE inhibitors (37.3%).
Almost half (46.6%) of the patients were treated with hypoli-
paemics, mainly statins (85.8%).
Healthcare resource consumption
Patients with paroxysmal or persistent AF had more
consultations with a specialist and more cardiovascular
hospitalizations related to AF and to its complications, com-
pared to patients with permanent AF (Table 5). A total
of 242 patients (18.4%) had been hospitalized at least
once for AF in the previous year: patients with persis-
tent and paroxysmal AF were hospitalized more frequently
(31.1% and 20.0%, respectively) than patients with perma-
nent AF (14.8%). Among hospitalized patients, 78.7% (n = 188
patients) were hospitalized at least once in an inpatient
setting (n = 241 hospitalizations) and 37.6% (n = 91 patients)
were hospitalized at least once in an outpatient setting
(n = 108 hospitalizations). The most common reasons for
inpatient hospitalization were for an arrhythmia or conduc-
tion disorder (24.2%), heart failure (23.8%), management
with a pacemaker, deﬁbrillator or other disposable intracar-
diac device (12.9%), and radiofrequency or surgical ablation
(11.3%). The most common reason for outpatient hospital-
ization was for external electric shock (49.5%).
Discussion
This observational study provides insights into the charac-
teristics and management of a contemporary population of
outpatients with either a history of or current AF in France.
Over half (52%) of the patients presented with permanent
AF and 48% with paroxysmal or persistent AF. Cardiovascu-
lar risk factors were present in 80% of patients, with a high
prevalence of hypertension and dyslipidaemia. The majority
of patients had received an antiarrhythmic treatment in the
previous 12 months, with a rate control strategy exclusively
preferred in 40.6%.
Patients in this French registry were older and gener-
ally sicker than those in other observational studies of AF,
with higher prevalences of hypertension, dyslipidaemia and
stroke/transient ischaemic attack [10,12,15,16]. The rate
of rheumatic heart disease was much higher (23.9%) than
reported in the French Étude en activité libérale de la ﬁb-
rillation auriculaire (ALFA; based on 1994 data) or German
AFNET (Central Registry of the German Competence NET-
work on Atrial Fibrillation; based on 2004—2006 data) (15.2%
and 2.5—5.3%, respectively) study, but was similar to that
reported in the Euro Heart Survey (21%) [12]. The higher pro-
portion of valvular AF included in our series could explain the
higher rate of cardioversion and concomitant treatments,
including antithrombotics.Antiarrhythmic treatment
Current guidelines from the American College of Car-
diology/American Heart Association/European Society of
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ardiology [4] recommend that the choice of a rate vs.
hythm control strategy should be guided by the patient’s
ymptoms, as rhythm control has shown no survival bene-
t over rate control [17—25], and places patients at higher
isk of drug-related adverse events [17,18,21] and hospital-
zations [21,23]. According to the French Haute Autorité de
anté (HAS) for AF management [5], prevention of cardio-
ascular events and reduction in cardiovascular mortality
re the main priorities for physicians. However, class I and
II antiarrhythmic drugs have never demonstrated a cardio-
ascular morbidity—mortality beneﬁt in patients with AF
17,26,27].
The use of antiarrhythmic therapy was very high in the
resent study, with over 95% of patients having received
ome form of treatment across all AF categories in the
revious 12 months. French physicians showed an overall
reference for a rhythm control strategy, with or without
ate control (59.4%), over a rate control strategy exclu-
ively (40.6%) in AF management. When broken down by
ype of AF, physicians opted for rhythm control in patients
ith paroxysmal AF and for rate control in those with per-
anent AF, who were generally older, as recommended
n the guidelines [4]. In the Euro Heart Survey of AF,
n patients with current AF symptoms, a rhythm con-
rol strategy was applied to 67% of patients and a rate
ontrol strategy exclusively in 27% [12]. Similarly, in the
erman AFNET study, 63.4% of patients received a combi-
ation of rhythm and rate control drugs; 21.3% of patients
ere given rhythm control drugs (classes I and III), mainly
hose with paroxysmal or persistent AF [15]. In the Reg-
stry on cardiac rhythm disorders assessing the control of
trial ﬁbrillation (RecordAF) [28] conducted in patients with
ecently diagnosed paroxysmal/persistent AF, rhythm- and
ate-control strategies were applied to 55% and 45% of
atients, respectively, at study inclusion. In France, the
se of rhythm-control strategies was approximately double
hat of rate-control strategies. Class III drugs and beta-
lockers were the most common AF medications prescribed
t baseline. While the proportion of patients in the present
tudy, treated exclusively with rhythm control therapies,
as higher, at 35.1%, the pattern of prescribing was simi-
ar.
ntithrombotic therapy
revention of thrombotic events remains a public health
igh priority in patients with AF. Clinical risk stratiﬁcation
s recommended to identify those at intermediate to high
isk of stroke [4]. Patients at high risk should receive war-
arin with an international normalized ratio in the range of
—3 (target 2.5) and those at low risk should receive aspirin
4]. The optimal strategy for patients at intermediate risk
emains the subject of debate, with inconsistency between
uidelines [4,29], but antithrombotic treatment with either
spirin or warfarin is recommended by the ACC/AHA/ESC
006 guidelines [4] and the ACCP [30]. In a recent retro-
pective study, the administration of an anticoagulant in
atients at intermediate risk of stroke (CHADS2 score = 1)
as associated with a lower rate of events compared with no
nticoagulant treatment (relative risk 0.42, 95% conﬁdence
nterval 0.29—0.60, p < 0.0001), whereas no such association
as present for patients treated with an antiplatelet [31].
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Table 5 Healthcare resource consumption related to AF, to its management and to its complications, in past 12 months.
Resources Paroxysmal
AF (n = 508)
Persistent
AF (n = 133)
Permanent
AF (n = 690)
p valuea Total
(n = 1331)
Number of consultations related to AF
(specialist)
3.0± 2.2 3.5± 2.7 2.6± 2.0 < 0.001 2.9± 2.1
Number of consultations related to AF
(general practitioner)
5.1± 4.0 4.7± 3.7 5.4± 4.1 0.09 5.2± 4.0
≥ 1 outpatient investigation 494 (97.8) 131 (98.5) 669 (97.7) 0.84 1294 (97.8)
Hospitalization
Patients with at least one hospitalization 100 (20.0) 41 (31.1) 101 (14.8) < 0.001 242 (18.4)
In outpatient setting 37 (37.0) 21 (51.2) 33 (32.7) 0.12 91 (37.6)
In inpatient setting 80 (82.5) 30 (73.2) 78 (77.2) 0.43 188 (78.7)
Number of outpatient hospitalizations 48 21 39 108
Reasons for outpatient hospitalization
External electric shock 20 (42.6) 15 (71.4) 18 (46.2) 53 (49.5)
Other 26 (55.3) 6 (28.6) 19 (48.7) 51 (47.7)
Multiple ticks 1 (2.1) 0 2 (5.1) 3 (2.8)
Number of inpatient hospitalizations 101 38 102 241
Primary reason of inpatient hospitalization
Hypertension 0 1 (2.6) 0 1 (0.4)
Stable angina or atypical chest pain 2 (2.0) 0 3 (3.0) 5 (2.1)
Unstable angina or myocardial infarction 0 0 2 (2.0) 2 (0.8)
Heart failure 14 (13.9) 5 (13.2) 38 (37.6) 57 (23.8)
Cardiovascular surgery 1 (1.0) 1 (2.6) 3 (3.0) 5 (2.1)
Interventional procedure (arterial
vascular access)
2 (2.0) 0 3 (3.0) 5 (2.1)
Arrhythmia or conduction disorder 33 (32.7) 17 (44.7) 8 (7.9) 58 (24.2)
Syncope 2 (2.0) 0 3 (3.0) 5 (2.1)
Non-fatal cardiac arrest 0 0 2 (2.0) 2 (0.8)
Placement of a pacemaker, deﬁbrillator or
intracardiac device
14 (13.9) 0 17 (16.8) 31 (12.9)
Radiofrequency or surgical ablation 17 (16.8) 7 (18.4) 3 (3.0) 27 (11.3)
Ischaemic stroke 2 (2.0) 1 (2.6) 3 (3.0) 6 (2.5)
Transient ischaemic attack 1 (1.0) 0 1 (1.0) 2 (0.8)
Symptomatic PAD 2 (2.0) 0 0 2 (0.8)
Major bleed 1 (1.0) 0 3 (3.0) 4 (1.7)
Adverse events of AF treatments 4 (4.0%) 2 (5.3%) 3 (3.0%) 9 (3.8%)
Other 6 (5.9) 4 (10.5) 9 (8.9) 19 (7.9)
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a Chi-square, analysis of variance or Fisher’s exact test.
n the present study, 26.1% of patients were at moderate
o high risk of stroke (CHADS2 > 2). Despite this observa-
ion, 94.4% of patients received an antithrombotic (83.4%
vitamin K antagonist and 21.9% an antiplatelet). The
verall use of antithrombotic therapy, driven by vitamin
antagonists, was highest among patients with perma-
ent AF, and reﬂected the rising CHADS2 score among
hese patients. In the German AFNET study, the propor-
ion of patients at moderate to high risk of stroke (CHADS2
core≥ 2 in 38.8% with paroxysmal, 53.4% with persistent
nd 62.1% with permanent AF) was broadly similar, and
he overall rate of use of antithrombotic medications was
lso comparable to that in the present study. The rates
f use of oral anticoagulants were 55.6% for paroxysmal
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bF, 74.4% for persistent AF and 70.7% for permanent AF.
orresponding data from the present study were 93.0%,
4.4% and 68.7%. The Euro Heart Survey also reported lower
ates of use of oral anticoagulant therapy (51%, 80%, 76%)
12].
ospitalizations and healthcare use
n average AF resulted in 2.9 visits to the specialist and
.2 visits to the GP per year and 348 hospitalizations for
331 patients. According to a US study, AF is the most
ommon cause of hospitalization for arrhythmia [32]. The
isk of hospitalization in AF patients is more than dou-
le that of patients in sinus rhythm [33]. In the Euro
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Heart Survey, between 30% and 43% of patients with AF
were hospitalized for a cardiovascular reason during 1-
year follow up [11]. In the COCAF study, 31.3% of patients
were hospitalized over a mean follow-up of 329± 120 days
[9]. The most frequent reasons for hospitalization in the
COCAF study were for cardioversion, heart failure, pace-
maker implantation or revision. In the present study, 18.4%
of patients were hospitalized at least once for an AF-
related cardiovascular reason in the preceding 12 months;
this rate is for sure under-estimated, considering that data
were collected retrospectively. It is important to note that
patients with persistent and paroxysmal AF were hospital-
ized more frequently (31.1% and 20.0%, respectively) than
patients with permanent AF (14.8%). Moreover, the aver-
age number of hospitalizations per patient was 1.5 for
paroxysmal AF, 1.4 for persistent AF and 1.4 for perma-
nent AF, illustrating the homogeneous burden of AF. As a
matter of fact, the rate of hospitalization (average num-
ber of hospitalizations per patient× rate of patients with
at least one hospitalization) was 30% for paroxysmal AF,
44.5% for persistent AF and 21% for permanent AF. The
most frequent reasons for inpatient hospitalization were
for heart failure or an arrhythmia or conduction disor-
der.
Study limitations
This study is subject to certain limitations, including the
lack of longitudinal follow-up data due to the retrospective
data collection. To minimize recruitment bias, cardiologists
were identiﬁed at random from a comprehensive national
database. Patient selection bias was diminished by enrolling
the ﬁrst eight consecutive patients who fulﬁlled the study
criteria. However, owing to the retrospective design of this
study a recruitment bias towards healthier AF patients is
likely. While AF was classiﬁed as paroxysmal, persistent or
permanent, follow-up at a later stage may provide addi-
tional data or re-classiﬁcation that will impact on the opti-
mal treatment strategy. Owing to the nature of the study,
we are unable to comment on the antiarrhythmic strategy
chosen in relation to the patients’ clinical characteristics.
Conclusions
These observational data provide a recent perspective of AF
care and comorbidities in France. One in two patients had
paroxysmal or persistent AF, and four-ﬁfths had at least one
cardiovascular risk factor. The rhythm control strategy was
preferred in patients with paroxysmal or persistent AF. The
use of antiarrhythmic and antithrombotic treatments was
very high, suggesting that French physicians are aware of
the need for such therapies in the AF population.
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